GSK and XenoPort to co-develop XP13512 for RLS and Neuropathic pain indications
UK-based drug major GlaxoSmithKline and California, USA-headquartered biopharmaceutical company Xenoport have entered into an exclusive agreement regarding the latter's compound XP13512. The deal, which covers the drug's development as a treatment for both restless legs syndrome and various neuropathic pain indications, applies worldwide, with the exclusion of certain Asian countries, where it has been already licensed to Japanese pharmaceutical firm Astellas Pharma.
Phase II/III trials in RLS and pain ongoing
The companies said that the drug, which is a patented prodrug of gabapentin (the active ingredient in Pfizer's anticonvulsant Neurtontin), has improved bioavailability when compared with other forms via its utilization of high capacity transport mechanisms in the gut. The firms added that it is currently in Phase III assessment for RLS and Phase II trials for neuropathic pain, and that results from previous clinical studies have been positive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze